Clinical Study

Br-101801-Ct-101- A Phase I, Open-Label, Multi-Center, Dose Escalation, And Expansion Study Of Br101801 In Adult Patients With Advanced Hematologic Malignancies

Posted Date: May 7, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

The main purpose of phase 1a of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of BR101801 in patients with relapsed/refractory advanced hematologic malignancies except acute leukemia and multiple myeloma. The main purpose of phase 1b is to assess tumor response and safety in specific advanced relapsed/refractory hematologic malignances at a dose of BR101801 identified in Phase Ia.


Phase Ia:Patients With Relapsed And/Or Refractory Relapsed/Refractory B-Cell Lymphoma, Cll/Sll, And Ptcl, Ecog 0-2, Life Expectancy More Than 3 Months, No Concurrent Malignant Disease, No Past Or Active Medical Condition Or Infection That May Impact Patients Safety Or Ability To Adhere To Study Treatment,


Leukemia, Multiple Myeloma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.